Tempus AI, Inc. Investor Presentation Q4 2025 and Full Year 2025 FEBRUARY 2026 Disclaimer This presentation contains forward-looking statements that reflect Tempus AI, Inc.'s (the "Company" or "Tempus") current expectations and projections with respect to, among other things, its financial condition, results of operations, plans, objectives, future performance and business. Forward-looking statements include all statements that are not historical facts. Such forward-looking statements are subject to various ...

Mainz Biomed to Present Industry Leading Results: 100% Sensitivity and 95% SpecificityBERKELEY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its participation in the renowned Digestive Disease Week (DDW) 2026 in Chicago, Illinois. At the conference the Company will present its poster titled “BLOOD-BASED MRNA SIGNATURE FOR DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA A ...

Raha highlighted volume growth in several areas, including MyRisk in oncology, with affected volumes up 14% and unaffected volumes up 11% year-over-year. He also pointed to an acceleration in Prolaris test volume growth to 12% year-over-year in the quarter, which he attributed to actions taken over the past two quarters, including incremental commercial investments focused on urologists.Wheeler said overall test volumes increased 2% year-over-year, while average revenue per test declined 2% year-over-year. ...

Myriad Genetics (NasdaqGS:MYGN) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Company ParticipantsAndrew Cooper - Director of Equity Research for Life Science Tools and Services and Diagnostics and Clinical LaboratoriesBen Wheeler - CFOBrian Donnelly - CCOLu Li - Director of Healthcare Equity ResearchMark Verratti - COOMatt Scalo - SVP of Investor RelationsSam Raha - President and CEOConference Call ParticipantsBill Bonello - Senior Research AnalystDan Brennan - Managing Director and Senior Research A ...

Myriad Genetics (NasdaqGS:MYGN) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Speaker11Good day, and thank you for standing by. Welcome to the Myriad Genetics fourth quarter and full year 2025 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? Developed al ...

Core Insights - Brown Capital Management's Small Company Fund underperformed in Q4 2025, with a decline of 1.50% compared to the Russell 2000® Growth index's gain of 1.22% [1] - The Fund's performance for the entire year of 2025 was down 11.46%, significantly lagging behind the Index's return of 13.01% [1] - The Fund's investment strategy is focused on company fundamentals, which showed strong revenue and earnings growth in 2025 [1] Company Focus: Veracyte, Inc. - Veracyte, Inc. is highlighted as a key holding in the Fund, with a market capitalization of $2.817 billion [2] - The stock price of Veracyte, Inc. closed at $35.63 on February 20, 2026, with a one-month return of -12.18% and a 52-week loss of 9.48% [2] - Veracyte holds a dominant market position with over 50% market share in its core products, Decipher and Afirma, which contributed more than 90% of revenue in 2024 [3] - The Decipher product has a market penetration of only 40%, indicating potential for double-digit growth in the coming years, while Afirma offers stability due to higher market penetration [3] - Veracyte's product pipeline could expand its market opportunity by over $3 billion, including tests for breast cancer, prostate cancer, and lung cancer [3] - The company turned profitable in 2024 and has shown significant margin expansion, with expectations for further growth [3] - Veracyte maintains a strong balance sheet with over $400 million in cash and has been free cash flow positive since 2023 [3]

GRAIL (NasdaqGS:GRAL) Q4 2025 Earnings call February 19, 2026 05:00 PM ET Company ParticipantsAaron Freidin - CFOAlex Dobbin - Director and Investor Relations ContactAndy Partridge - Chief Commercial OfficerBob Ragusa - CEODoug Schenkel - Managing Director of Life Science Tools and DiagnosticsJosh Ofman - PresidentSir Harpal Kumar - Chief Scientific Officer and President of InternationalSubbu Nambi - Managing DirectorConference Call ParticipantsCatherine Schulte - Senior Research AnalystDan Brennan - Senior ...

Financial Data and Key Metrics Changes - Fourth quarter revenue was $43.6 million, an increase of $5.3 million, or 14%, compared to Q4 2024 [20] - Full year total revenue was $147.2 million, up 17% from 2024, with screening revenue of $138.6 million, up 28% [20][21] - Net loss for Q4 2025 was $99.2 million, a 2% increase compared to Q4 2024, while full year net loss improved by 80% to $408.4 million [22] - Non-GAAP adjusted gross profit for Q4 2025 was $23.1 million, a 29% increase compared to Q4 2024 [23] - Adjusted EBITDA for Q4 2025 was -$71.8 million, an improvement of 15% compared to Q4 2024 [24] Business Line Data and Key Metrics Changes - U.S. Galleri tests volume grew 36% to over 185,000 tests in 2025, with revenue growth of 26% [8] - Development services revenue decreased by 49% to $8.6 million in 2025 [21] Market Data and Key Metrics Changes - The prescriber base for Galleri increased by 30% to approximately 17,000 providers [8] - The company is focused on expanding awareness of multi-cancer early detection and anticipates growing conviction in Galleri among patients, providers, and employers [9] Company Strategy and Development Direction - The company plans to expand its field sales and medical team to drive commercial momentum [7] - The PMA submission to the FDA for Galleri marks a critical step in making the test available to more people [9] - The company aims to leverage strong results from clinical trials to expand partnerships and access to Galleri [28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for Galleri to bend the cancer mortality curve at a population scale [16] - The company reiterated guidance for Galleri sales growth of 22%-32% and cash burn for 2026 to be no more than $300 million [26] - The cash runway extends into 2030, positioning the company well for future growth [26] Other Important Information - The NHS-Galleri trial showed a fourfold increase in cancer detection rates and a significant reduction in stage 4 cancer diagnoses [5][12] - The company plans to present full data from the NHS-Galleri and PATHFINDER 2 studies in mid-2026 [27][90] Q&A Session Summary Question: Will the FDA approval decision be impacted by missing the stage shift endpoint? - Management confirmed that the FDA will focus on clinical performance and safety, and there is no obvious correlation between the NHS-Galleri study results and the FDA's view on the test [31] Question: How does the NHS-Galleri trial impact the strategy to expand Galleri internationally? - Management believes the strong data from the NHS-Galleri trial will be compelling for discussions with other countries [36] Question: What is the probability of FDA approval unchanged as a result of the NHS Galleri readout? - Management indicated that the probability remains unchanged, focusing on clinical performance and safety in their submission [45][50] Question: What are the next steps regarding the NHS and the multi-cancer early detection tests? - Management has ongoing conversations with the NHS and anticipates that they will want to see full results before engaging in meaningful discussions [62] Question: How will Medicare evaluate the NHS trial data for coverage? - Management believes they will provide a robust package of data to Medicare, including substantial stage 4 reduction and overall clinical performance [67]

Core Insights - Castle Biosciences announced the publication of a study demonstrating that its AdvanceAD-Tx test can effectively identify patients with moderate-to-severe atopic dermatitis who are more likely to respond positively to JAK inhibitor therapy compared to Th2-targeted therapies [1][2][8] Group 1: Study Findings - The AdvanceAD-Tx test identified approximately 30% of patients as having a JAK Inhibitor Responder Profile, who were 5.5 times more likely to achieve at least 90% improvement in Eczema Area and Severity Index (EASI-90) within three months compared to those on Th2-targeted therapies (45.5% vs. 8.3%, p=0.021) [3][6] - Patients with the JAK Inhibitor Responder Profile achieved a response nearly four times faster than those treated with Th2-targeted therapies (p=0.049) [3][6] - The study also indicated that patients with a JAK Inhibitor Responder Profile reported higher rates of "no itch" (45.5% vs. 8.3%, p=0.021) and remained flare-free by three months (54.5% vs. 16.7%, p=0.041) [6][8] Group 2: Clinical Implications - The findings suggest that aligning systemic therapy selection with an individual patient's molecular profile can streamline care, reduce unnecessary treatment changes, and accelerate meaningful clinical improvement [5][8] - The AdvanceAD-Tx test provides objective molecular insights that can help clinicians make more confident, evidence-based treatment decisions earlier in the patient journey [5][8] - Patients identified with a Th2 Molecular Profile showed no statistically significant differences in outcomes when treated with either JAK inhibitors or Th2-targeted therapies, emphasizing the importance of personalized treatment decisions [4][8] Group 3: Product Overview - AdvanceAD-Tx is a non-invasive gene expression profile test designed for patients aged 12 years and older with moderate-to-severe atopic dermatitis, evaluating 487 genes across 12 inflammatory and cutaneous biology pathways [2][6] - The test requires only lesional skin scrapings, eliminating the need for biopsies, and classifies patients into either a JAK Inhibitor Responder Profile or a Th2 Molecular Profile [2][7]